Report Detail
Global (United States, European Union and China) Anti-Obesity Prescription Drugs Market Research Report 2019-2025
- RnM3573639 |
- 04 July, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
In 2019, the market size of Anti-Obesity Prescription Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of 5.0% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anti-Obesity Prescription Drugs.
This report studies the global market size of Anti-Obesity Prescription Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Anti-Obesity Prescription Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Market Segment by Product Type
Orlistat
Phentermine and Topiramate
Bupropion and Naltrexone
Lorcaserin
Liraglutide
Market Segment by Application
Pediatric
Adult
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Anti-Obesity Prescription Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Anti-Obesity Prescription Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Anti-Obesity Prescription Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Orlistat
- 1.3.3 Phentermine and Topiramate
- 1.3.4 Bupropion and Naltrexone
- 1.3.5 Lorcaserin
- 1.3.6 Liraglutide
- 1.4 Market Segment by Application
- 1.4.1 Global Anti-Obesity Prescription Drugs Market Share by Application (2019-2025)
- 1.4.2 Pediatric
- 1.4.3 Adult
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Anti-Obesity Prescription Drugs Market Size
- 2.1.1 Global Anti-Obesity Prescription Drugs Revenue 2014-2025
- 2.1.2 Global Anti-Obesity Prescription Drugs Sales 2014-2025
- 2.2 Anti-Obesity Prescription Drugs Growth Rate by Regions
- 2.2.1 Global Anti-Obesity Prescription Drugs Sales by Regions 2014-2019
- 2.2.2 Global Anti-Obesity Prescription Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Anti-Obesity Prescription Drugs Sales by Manufacturers
- 3.1.1 Anti-Obesity Prescription Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Anti-Obesity Prescription Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Anti-Obesity Prescription Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Anti-Obesity Prescription Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Anti-Obesity Prescription Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Anti-Obesity Prescription Drugs Price by Manufacturers
- 3.4 Key Manufacturers Anti-Obesity Prescription Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Anti-Obesity Prescription Drugs Market
- 3.6 Key Manufacturers Anti-Obesity Prescription Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Orlistat Sales and Revenue (2014-2019)
- 4.1.2 Phentermine and Topiramate Sales and Revenue (2014-2019)
- 4.1.3 Bupropion and Naltrexone Sales and Revenue (2014-2019)
- 4.1.4 Lorcaserin Sales and Revenue (2014-2019)
- 4.1.5 Liraglutide Sales and Revenue (2014-2019)
- 4.2 Global Anti-Obesity Prescription Drugs Sales Market Share by Type
- 4.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Type
- 4.4 Anti-Obesity Prescription Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Anti-Obesity Prescription Drugs Sales by Application
6 United States
- 6.1 United States Anti-Obesity Prescription Drugs Breakdown Data by Company
- 6.2 United States Anti-Obesity Prescription Drugs Breakdown Data by Type
- 6.3 United States Anti-Obesity Prescription Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Anti-Obesity Prescription Drugs Breakdown Data by Company
- 7.2 European Union Anti-Obesity Prescription Drugs Breakdown Data by Type
- 7.3 European Union Anti-Obesity Prescription Drugs Breakdown Data by Application
8 China
- 8.1 China Anti-Obesity Prescription Drugs Breakdown Data by Company
- 8.2 China Anti-Obesity Prescription Drugs Breakdown Data by Type
- 8.3 China Anti-Obesity Prescription Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Company
- 9.2 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Type
- 9.3 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Application
- 9.4 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Anti-Obesity Prescription Drugs Sales by Countries
- 9.4.2 Rest of World Anti-Obesity Prescription Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 F Hoffmann La Roche Ltd
- 10.1.1 F Hoffmann La Roche Ltd Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.1.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.1.5 F Hoffmann La Roche Ltd Recent Development
- 10.2 Orexigen Therapeutics
- 10.2.1 Orexigen Therapeutics Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.2.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.2.5 Orexigen Therapeutics Recent Development
- 10.3 Novo Nordisk A/s
- 10.3.1 Novo Nordisk A/s Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.3.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.3.5 Novo Nordisk A/s Recent Development
- 10.4 Arena Pharmaceuticals
- 10.4.1 Arena Pharmaceuticals Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.4.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.4.5 Arena Pharmaceuticals Recent Development
- 10.5 Glaxosmithkline
- 10.5.1 Glaxosmithkline Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.5.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.5.5 Glaxosmithkline Recent Development
- 10.6 Vivus
- 10.6.1 Vivus Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.6.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.6.5 Vivus Recent Development
- 10.7 Boehringer Ingelheim
- 10.7.1 Boehringer Ingelheim Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.7.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.7.5 Boehringer Ingelheim Recent Development
- 10.8 Alizyme
- 10.8.1 Alizyme Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
- 10.8.4 Anti-Obesity Prescription Drugs Product Introduction
- 10.8.5 Alizyme Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Anti-Obesity Prescription Drugs Sales Channels
- 11.2.2 Anti-Obesity Prescription Drugs Distributors
- 11.3 Anti-Obesity Prescription Drugs Customers
12 Market Forecast
- 12.1 Global Anti-Obesity Prescription Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Anti-Obesity Prescription Drugs Sales Forecast by Type
- 12.3 Global Anti-Obesity Prescription Drugs Sales Forecast by Application
- 12.4 Anti-Obesity Prescription Drugs Forecast by Regions
- 12.4.1 Global Anti-Obesity Prescription Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Anti-Obesity Prescription Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Anti-Obesity Prescription Drugs . Industry analysis & Market Report on Anti-Obesity Prescription Drugs is a syndicated market report, published as Global (United States, European Union and China) Anti-Obesity Prescription Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Anti-Obesity Prescription Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
